Results 81 to 90 of about 4,964,104 (350)

Exploration of heterogeneity and recurrence signatures in hepatocellular carcinoma

Molecular Oncology, EarlyView.
This study leveraged public datasets and integrative bioinformatic analysis to dissect malignant cell heterogeneity between relapsed and primary HCC, focusing on intercellular communication, differentiation status, metabolic activity, and transcriptomic profiles.
Wen‐Jing Wu, Jianchao Wang, Fuqing Chen, Xuefeng Wang, Bin Lan, Ruyi Fu, Hong Wen, Fangfang Chen, Wei Hong, Tian‐Yu Tang, Ying He, Gang Chen, Jianyin Zhou, Hai‐Long Piao, Di Chen, Shu‐Yong Lin   +15 more
wiley   +1 more source

The Australian Medical Oncologist Workforce Survey: The profile and challenges of medical oncology.

Seminars in Oncology, 2018
BACKGROUND The aim of this study was to understand the current and future challenges for the Australian medical oncologist workforce. METHODS Utilising an on-line self-administered questionnaire, this cross-sectional study collected data from members ...
Z. Lwin, A. Broom, D. Sibbritt, K. Francis, C. Karapetis, D. Karikios, R. Harrup   +6 more
semanticscholar   +1 more source

Comparing self‐reported race and genetic ancestry for identifying potential differentially methylated sites in endometrial cancer: insights from African ancestry proportions using machine learning models

Molecular Oncology, EarlyView.
Integrating ancestry, differential methylation analysis, and machine learning, we identified robust epigenetic signature genes (ESGs) and Core‐ESGs in Black and White women with endometrial cancer. Core‐ESGs (namely APOBEC1 and PLEKHG5) methylation levels were significantly associated with survival, with tumors from high African ancestry (THA) showing ...
Huma Asif, J. Julie Kim
wiley   +1 more source

European Society for Medical Oncology (ESMO)

Journal of Thoracic Oncology, 2023

semanticscholar   +1 more source

Delivery of Global Cancer Care: An International Study of Medical Oncology Workload

Journal of Global Oncology, 2017
Background To our knowledge, there is no literature that has described medical oncology (MO) workload in the global context. Here, we report results of an international study of global MO workload.
A. Fundytus, R. Sullivan, V. Vanderpuye, B. Šeruga, G. Lopes, N. Hammad, M. Sengar, W. Hopman, M. Brundage, C. Booth   +9 more
semanticscholar   +1 more source

The atypical KRASQ22K mutation directs TGF‐β response towards partial epithelial‐to‐mesenchymal transition in patient‐derived colorectal cancer tumoroids

Molecular Oncology, EarlyView.
TGF‐β has a complex role in cancer, exhibiting both tumor‐suppressive and tumor‐promoting properties. Using a series of differentiated tumoroids, derived from different stages and mutational background of colorectal cancer patients, we replicate this duality of TGF‐β in vitro. Notably, the atypical but highly aggressive KRASQ22K mutation rendered early‐
Theresia Mair, Philip König, Milena Mijović, Jessica Kalla, Anil Baskan, Loan Tran, Kristina Draganić, Pedro Morata Saldaña, Carlos Uziel Pérez Malla, Janette Pfneissl, Andreas Tiefenbacher, Julijan Kabiljo, Velina S. Atanasova, Lisa Wozelka‐Oltjan, Leonhard Müllauer, Michael Bergmann, Raheleh Sheibani‐Tezerji, Gerda Egger   +17 more
wiley   +1 more source

ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016

Annals of Oncology, 2016
Oncology is driven by an exponentially increasing complexity. As an example, the use of molecular profiling or the determination of molecularly based biomarkers for the selection of the appropriate targeted therapy has now become routine in clinical ...
C. Dittrich, M. Kosty, S. Jezdic, D. Pyle, R. Berardi, J. Bergh, N. E. El Saghir, Jean-Pierre Lotz, P. Österlund, N. Pavlidis, G. Purkalne, H. Carraway, Julia Lee Close, J. Gilbert, Carsten Bokemeyer, Andrés Cervantes, Y. Ohe, Miklos Pless, Keith McGregor, Katharine Fumassoli, Roberta Candiani, G. Bricalli, Tanya Kenny, N. Latino, Marina Cogo, Vanessa Pavinato, Vanessa Marchesi, A. Awada, Susana Banerjee, S. Bhatia, J. Bogaerts, J. Buckner, F. Cardoso, P. Casali, E. Chu, B. Coiffier, R. Connolly, S. Coupland, L. de Petris, M. D. De Santis, Elisabeth G.E. de Vries, Don S. Dizon, J. Duff, L. Duska, A. Eniu, M. Ernstoff, E. Felip, Martin F. Fey, N. Girard, A. Glaudemans, Priya K. Gopalan, A. Grothey, Stephen M. Hahn, D. Hanna, C. Herold, J. Herrstedt, K. Homicsko, Dennie V. Jones, L. Jost, U. Keilholz, S. Khan, A. Kiss, C. Köhne, R. Kunstfeld, H. Lenz, S. Lichtman, L. Licitra, T. Lion, S. Litière, Lifang Liu, Patrick J. Loehrer, Merry Jennifer Markham, B. Markman, M. Mayerhoefer, Johannes G. Meran, O. Michielin, Elizabeth Charlotte Moser, G. Mountzios, T. Moynihan, T. Nielsen, K. Öberg, A. Palumbo, Fedro Alessandro Peccatori, M. Pfeilstöcker, C. Raut, S. Remick, M. Robson, P. Rutkowski, R. Salgado, L. Schapira, E. Schernhammer, M. Schlumberger, H. Schmoll, L. Schnipper, C. Sessa, Charles L. Shapiro, Julie Steele, Cora N. Sternberg, Stiefel, F. Strasser, R. Stupp, R. Sullivan, J. Tabernero, L. Travado, M. Verheij, E. Voest, E. Vokes, J. V. Von Roenn, Jeffrey Weber, H. Wildiers, Y. Yarden   +110 more
semanticscholar   +1 more source

A large‐scale retrospective study in metastatic breast cancer patients using circulating tumour DNA and machine learning to predict treatment outcome and progression‐free survival

Molecular Oncology, EarlyView.
There is an unmet need in metastatic breast cancer patients to monitor therapy response in real time. In this study, we show how a noninvasive and affordable strategy based on sequencing of plasma samples with longitudinal tracking of tumour fraction paired with a statistical model provides valuable information on treatment response in advance of the ...
Emma J. Beddowes, Mario Ortega Duran, Solon Karapanagiotis, Alistair Martin, Meiling Gao, Riccardo Masina, Ramona Woitek, James Tanner, Fleur Tippin, Justine Kane, Jonathan Lay, Anja Brouwer, Stephen‐John Sammut, Suet‐Feung Chin, Davina Gale, Dana W. Y. Tsui, Sarah‐Jane Dawson, Nitzan Rosenfeld, Maurizio Callari, Oscar M. Rueda, Carlos Caldas   +20 more
wiley   +1 more source

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology

Clinical and Translational Oncology, 2017
This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
Ramon Colomer, I. Aranda-López, J. Albanell, T. García-Caballero, E. Ciruelos, M. Á. López-García, Javier Cortés, Federico Rojo, Miguel Martín, J. Palacios-Calvo   +9 more
semanticscholar   +1 more source

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal‐like and malignant urothelial cells

Molecular Oncology, EarlyView.
Loss of the frequently mutated chromatin remodeler ARID1A, a subunit of the SWI/SNF cBAF complex, results in less open chromatin, alternative splicing, and the failure to stop cells from progressing through the cell cycle after DNA damage in bladder (cancer) cells. Created in BioRender. Epigenetic regulators, such as the SWI/SNF complex, with important
Rebecca M. Schlösser, Florian Krumbach, Eyleen Corrales, Geoffroy Andrieux, Christian Preisinger, Franziska Liss, Alexandra Golzmann, Melanie Boerries, Kerstin Becker, Ruth Knüchel, Stefan Garczyk, Bernhard Lüscher   +11 more
wiley   +1 more source